Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer's Disease in the United States: A Cost-Effectiveness Analysis.

Yunusa, Ismaeel; Alsahali, Saud; Rane, Amey; Eguale, Tewodros

Yunusa, Ismaeel; Alsahali, Saud; Rane, Amey; Eguale, Tewodros.

Afiliación

Yunusa I; Center for Outcomes Research and Evaluation, Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC, USA.
Alsahali S; Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Rane A; MCPHS University, Boston, MA, USA.
Eguale T; MCPHS University, Boston, MA, USA.

J Alzheimers Dis Rep ; 5(1): 705-713, 2021.

Article en En | MEDLINE | ID: mdl-34755044

Palabras clave

Alzheimer's disease; cholinesterase inhibitors; cost-effectiveness analysis; donepezil; memantine; quality-adjusted life years; rivastigmine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: J Alzheimers Dis Rep Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google